|
|
|
Male |
Female |
|
|
|
|
Cravedi 2007 |
Italy |
Matched-cohort study |
8 |
4 |
57.0±13.0 |
12 |
B
cell-driven treatment* |
10.3±8.9 |
Sugiura 2010 |
Japan |
Prospective clinical trial |
2 |
2 |
66.5±8.7 |
6 |
1×375
mg/m2 (n = 4) (maximum 500 mg) |
4.3±2.6 |
Ramachandran 2016 |
India |
Prospective clinical trial |
—— |
—— |
—— |
6 |
100 mg of RTX (n = 6) |
12.1±10.8 |
Moroni 2017
|
Italy
|
Prospective single-center experience
|
23
|
11
|
52.8±15.2
|
24
|
1×375 mg/m2 (n = 18)
2×375 mg/m2 (n = 16)
|
11.9±8.2
|
Bagchi 2018 |
India |
Multicentric retrospective study |
14 |
7 |
33.3±12.3 |
12 |
two doses of RTX (500mg each) infusion 7 days apart |
6.2±2.2 |
Fenoglio (LD) 2020 |
Italy |
Prospective cohort experience |
5 |
9 |
64.4±10.8 |
24 |
1×375 mg/m2 (n = 14) |
7.5±4.8 |
Remuzzi 2002 |
Italy |
Prospective single-center experience |
—— |
—— |
50.1±45.6 |
20 |
4×375 mg/m2
|
8.6±1.5 |
Ruggenenti 2003 |
Italy |
Prospective single-center experience |
—— |
—— |
52.5±19.6 |
12 |
4×375 mg/m2
|
8.6±4.2 |
Ruggenenti (pro) 2006 |
Italy |
Retrospective cohort and prospective
cohort |
4 |
5 |
51.2±13.2 |
12 |
4×375 mg/m2
|
8.9±5.3 |
Fervenza 2008 |
Canada |
Prospective single-center experience |
13 |
2 |
47.0±8.0 |
12 |
4×375 mg/m2
|
13.0±5.7 |
Fervenza 2010 |
Canada |
Prospective single-center experience |
17 |
3 |
48.6±12.9 |
24 |
4×375 mg/m2
|
11.9±4.9 |
Busch 2013 |
Germany |
Prospective single-center experience |
10 |
4 |
47.0±14.0 |
12 |
4×375 mg/m2
|
8.6±1.5 |